Akeso: A Leading Innovator in Biopharmaceuticals
About Akeso
- Akeso is a commercial-stage biopharmaceutical company focused on developing and manufacturing innovative drugs for cancer, autoimmune diseases, inflammation, and metabolic disorders.
- The company has a robust pipeline of over 50 innovative assets, with 19 in the clinical stage and 3 already approved.
Key Products
Cadonilimab
Cadonilimab is a first-in-class PD-1CTLA-4 bi-specific immunotherapy drug developed by Akeso. It was approved by the NMPA in June 2022, making it the first commercialized PD-1 based bispecific drug globally.
Ivonescimab
Ivonescimab is a novel PD-1VEGF bi-specific immunotherapy drug independently developed by Akeso. It has recently made significant strides in the treatment of advanced lung cancer and is currently in Phase III clinical trials.
Research and Development
Akeso is actively developing a diverse pipeline of over 50 innovative assets. The company has a strong commitment to research and development, with a team of experienced scientists and researchers.
Investment Opportunities
Akeso is a publicly traded company on the Hong Kong Stock Exchange (stock code: 9926HK). The company offers attractive investment opportunities for investors seeking exposure to the growing biopharmaceutical industry.
Partnerships and Collaborations
Akeso has established partnerships with leading biopharmaceutical companies around the world. These partnerships enable the company to leverage its expertise and resources to develop and commercialize innovative drugs.
Recent News and Updates
- Akeso announced positive results from three investigator-initiated trials of its bispecific IO drug cadonilimab.
- The company has completed patient enrollment in a head-to-head study of ivonescimab compared with tislelizumab in combination with chemotherapy.
- Akeso will participate as an exhibitor at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.
Conclusion
Akeso is a leading innovator in the biopharmaceutical industry. The company's robust pipeline of innovative drugs, strong commitment to research and development, and strategic partnerships position it for continued growth and success.
Comments